A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Inclusion Criteria:

* The subject will participate voluntarily and sign the informed consent form.
* Female, aged ≥18 years when signing the informed consent form.
* Recurrent or metastatic cervical cancer (pathological types include squamous cell carcinoma, adenocarcinoma) which is not suitable for radical treatment such as surgery and radiotherapy.
* At least one measurable lesion is needed.
* The Eastern Collaborative Oncology Group (ECOG) physical status score was 0 or 1.
* Adequate reserves of organ function is needed.

Exclusion Criteria:

* Active autoimmune disease.
* Central nervous system (CNS) metastasis.
* Concomitant diseases such as cardiovascular and cerebrovascular diseases.
* Fistula of female genital tract.
* Diseases for which systemic corticosteroids or other immunosuppressive agents are planned to be used during the study treatment.
* Previous recipients of immune checkpoint inhibitors.
* Received systemic antitumor drugs such as chemotherapy and targeted therapy within 4 weeks before the first use of the experimental drug; Received proprietary Chinese medicine with anti-tumor indications within 2 weeks before the first use of the experimental drug.
* Received radical concurrent chemoradiotherapy or adjuvant chemoradiotherapy within 12 weeks before the first use of the investigational drug; Received palliative radiotherapy (e.g., reductive radiotherapy for pain or bleeding) or other local treatments (e.g., radiofrequency ablation, transarterial chemoembolization, etc.) within 2 weeks before the first use of the investigational drug.
* History of immunodeficiency.
* History of allogeneic hematopoietic stem cell transplantation or organ transplantation.